| 篇名 |
Life‑threatening bowel complications following anti‑tumor necrosis factor antibody therapy for patients with inflammatory bowel disease: A report of three cases in Taiwan |
| 作者 |
Tzu‑Chi Hsu, Ming‑Jen Chen, Po‑Li Tsai, Wen‑Chun Sun, Ping‑Wei Lin, Wei‑Chen Lin, Horng‑Yuan Wang |
| 卷期/出版年月 |
55卷6期 (2022/11) |
| 頁次 |
229-233 |
| 摘要 |
Incidence of inflammatory bowel disease (IBD) in Taiwan and the experience of the management of
serious complications is much lower than in Western countries. The authors just want to alert readers
that anti‑tumor necrosis factor (TNF) is not without life‑threatening complications. Three serious
complications were described, including surgical management and outcomes following the application
of anti‑TNF monoclonal antibody therapy for IBD. Case 1 involved a 25‑year‑old man treated with five
doses of adalimumab for moderate control of Crohn’s disease (CD). Six months later, he experienced
severe intestinal obstruction, which necessitated right hemicolectomy with ileocolic anastomosis. He
recovered postsurgery. Case 2 involved a 54‑year‑old man treated with adalimumab for intractable
ulcerative colitis. Ten days after the second dose of adalimumab, an emergent subtotal colectomy with
ileostomy was performed for a transverse colon perforation with peritonitis. The patient underwent
an ileal pouch operation a year later. Case 3 was based on a 16‑year‑old male patient treated with six
doses of an infliximab biosimilar for CD; thereafter, an emergent subtotal colectomy with ileostomy and
Hartmann’s pouch was performed for peritonitis with the presence of a perforated gastrocolic fistula
tract. He had no serious complications following an uneventful recovery period. Creating awareness of
serious complications associated with biologic treatments and offering appropriate patient management,
including surgical treatment, is beneficial to patients. |
| 關鍵詞 |
Anti‑TNF antibody, colectomy, inflammatory bowel disease, perforation |
| 分類 |
Case Report |
